Hemispherian AS is an innovative preclinical pharmaceutical company based in Oslo. The company specializes in the development of a new class of small molecule drugs, with a particular focus on targeted therapy for aggressive cancers. Their lead compound is currently in advanced preclinical development for the treatment of glioblastoma, a type of brain cancer.
The company's approach includes a unique mechanism of action that aims to restore the epigenetic balance in cells. The treatment is designed to be targeted, which helps it to be well tolerated by normal tissues. Hemispherian AS has received support from both Norwegian and European public entities, and they are open to collaboration to strengthen their network and promote clinical studies.